313 related articles for article (PubMed ID: 19840568)
1. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
[TBL] [Abstract][Full Text] [Related]
2. Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes.
Tizón-Marcos H; Bertrand OF; Rodés-Cabau J; Larose E; Gaudreault V; Bagur R; Gleeton O; Courtis J; Roy L; Poirier P; Costerousse O; De Larochellière R
Am Heart J; 2009 Apr; 157(4):740-5. PubMed ID: 19332204
[TBL] [Abstract][Full Text] [Related]
3. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
4. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
[TBL] [Abstract][Full Text] [Related]
5. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
[TBL] [Abstract][Full Text] [Related]
6. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy.
Bertrand OF; Larose E; Rodés-Cabau J; Gleeton O; Taillon I; Roy L; Poirier P; Costerousse O; Larochellière RD
Am Heart J; 2009 Jan; 157(1):164-9. PubMed ID: 19081414
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes in patients > or =70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndrome.
Bagur R; Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Tizón-Marcos H; Gleeton O; Nguyen CM; Roy L; Costerousse O; De Larochellière R
Am J Cardiol; 2009 Sep; 104(5):624-9. PubMed ID: 19699334
[TBL] [Abstract][Full Text] [Related]
8. Incidence, range, and clinical effect of hemoglobin changes within 24 hours after transradial coronary stenting.
Bertrand OF; Larose E; Rodés-Cabau J; Rinfret S; Déry JP; Bagur R; Gleeton O; Nguyen CM; Proulx G; De Larochellière R; Poirier P; Costerousse O; Roy L
Am J Cardiol; 2010 Jul; 106(2):155-61. PubMed ID: 20598996
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
Capuano C; Sesana M; Leonzi O; Cuccia C
J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
12. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Cuisset T; Hamilos M; Sarma J; Sarno G; Wyffels E; Vanderheyden M; Barbato E; Bartunek J; De Bruyne B; Wijns W
Am J Cardiol; 2008 Jun; 101(12):1700-3. PubMed ID: 18549843
[TBL] [Abstract][Full Text] [Related]
13. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
[TBL] [Abstract][Full Text] [Related]
14. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
15. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
16. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
19. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
Brener SJ; Steinhubl SR; Berger PB; Brennan DM; Topol EJ;
J Invasive Cardiol; 2007 Jul; 19(7):287-90. PubMed ID: 17620671
[TBL] [Abstract][Full Text] [Related]
20. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
